Rexahn Pharmaceuticals, Inc. (NYSE: RNN) announced that additional interim clinical data from an ongoing Phase IIa study of its novel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE